Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZT-101
- Development stage
- Unknown
- Lead developer
- AZTherapies
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
**AZT-101** is an inhaled formulation of cromolyn sodium developed by AZTherapies for neurological indications. Cromolyn sodium is a mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and cytokines from mast cells, thereby targeting neuroinflammation. AZTherapies is evaluating it as part of the combination therapy ALZT-OP1a (cromolyn sodium + sildenafil) in Phase 2 trials for post-ischemic stroke cognitive impairment (PSCI).[8]
- Other names
- inhaled cromolyn sodium
Beyond the preview
Go deeper on AZT-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZT-101.